FDA Warning Letter criticizes Supplier Qualification
Recommendation
21-23 May 2025
Copenhagen, Denmark
Initial and Continuous Professional Training for GMP Auditors
Register now for ECA's GMP Newsletter
CMO Supplier Qualification and the respective contracts in outsourcing activities are always hot topics in inspections. The U.S. Food and Drug Administration (FDA) recently posted a Warning Letter sent to a pharmaceutical company in the US criticizing their supplier qualification and oversight. The inspection was scheduled because of problems at the company's CMO.
For example, the company "failed to have adequate supplier qualification procedures to ensure that the drug products received" from CMOs "were manufactured in compliance with CGMP." They also "failed to have adequate procedures" to ensure tht all drug products produced for the firm met "appropriate quality attributes".
The company now has to evaluate the supplier and CMO qualification program, "including a plan to conduct periodic audits". In the Warning Letter, the FDA clearly points out that the company is responsible for the quality of the drugs "regardless of agreements in place" with CMOs.
Related GMP News
04.12.2024Discarded Batch Documentation again found during Inspection
30.10.2024From missing Analysis to Brand Protection Violations - FDA Warning Letter to Canadian Manufacturer
23.10.2024Root Cause Analysis: What can be found in FDA Warning Letters?
23.10.2024Do you want to host FDA Staff? FDA announces Experiential Learning Site Visit Program
09.10.2024Management circumvents Quality Department in Deviation Classification - FDA Warning Letter
09.10.2024Despite MRA: Why does the FDA inspect so frequently in the EU?